Riccardo  Perfetti net worth and biography

Riccardo Perfetti Biography and Net Worth

Riccardo Perfetti, M.D., Ph.D. has served as Chief Medical Officer of Applied Therapeutics since August 2018. Before joining us, Dr. Perfetti served as a Senior Medical Officer, Vice President and Head of Global Medical Affairs, Diabetes and Cardiovascular Business Unit at Sanofi S.A., a publicly traded pharmaceutical company, from October 2007 to August 2018. Prior to joining Sanofi, Dr. Perfetti served in various roles at Amgen Inc., a publicly traded biopharmaceutical company, including as a Director and Global Development Leader in diabetes, obesity, metabolism and endocrinology from December 2004 to August 2007. Dr. Perfetti was previously an associate professor of medicine at University of California in Los Angeles and a professor of medicine at the National Institutes of Health (NIH). Dr. Perfetti practiced as an endocrinologist at Cedars-Sinai Medical Center and also served as Director of the Diabetes Research Laboratory and Director of the Outpatient Diabetes Program. Dr. Perfetti received his M.D. and Ph.D. in Endocrinology from University La Sapienza in Rome, Italy and received post-graduate training in endocrinology and molecular biology at NIH.

What is Riccardo Perfetti's net worth?

The estimated net worth of Riccardo Perfetti is at least $7.23 million as of March 14th, 2024. Dr. Perfetti owns 1,031,537 shares of Applied Therapeutics stock worth more than $7,231,074 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Perfetti may own. Additionally, Dr. Perfetti receives a salary of $858,000.00 as Insider at Applied Therapeutics. Learn More about Riccardo Perfetti's net worth.

How old is Riccardo Perfetti?

Dr. Perfetti is currently 63 years old. There are 5 older executives and no younger executives at Applied Therapeutics. Learn More on Riccardo Perfetti's age.

What is Riccardo Perfetti's salary?

As the Insider of Applied Therapeutics, Inc., Dr. Perfetti earns $858,000.00 per year. Learn More on Riccardo Perfetti's salary.

How do I contact Riccardo Perfetti?

The corporate mailing address for Dr. Perfetti and other Applied Therapeutics executives is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. Applied Therapeutics can also be reached via phone at (212) 220-9226 and via email at [email protected]. Learn More on Riccardo Perfetti's contact information.

Has Riccardo Perfetti been buying or selling shares of Applied Therapeutics?

During the past quarter, Riccardo Perfetti has sold $597,233.56 of Applied Therapeutics stock. Most recently, Riccardo Perfetti sold 110,804 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $5.39, for a transaction totalling $597,233.56. Following the completion of the sale, the insider now directly owns 1,031,537 shares of the company's stock, valued at $5,559,984.43. Learn More on Riccardo Perfetti's trading history.

Who are Applied Therapeutics' active insiders?

Applied Therapeutics' insider roster includes Riccardo Perfetti (Insider), Shoshana Shendelman (CEO), and Charles Silberstein (CFO). Learn More on Applied Therapeutics' active insiders.

Are insiders buying or selling shares of Applied Therapeutics?

During the last twelve months, Applied Therapeutics insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $65,400.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 849,027 shares worth more than $3,436,223.39. The most recent insider tranaction occured on March, 14th when CEO Shoshana Shendelman sold 318,573 shares worth more than $1,717,108.47. Insiders at Applied Therapeutics own 19.1% of the company. Learn More about insider trades at Applied Therapeutics.

Information on this page was last updated on 3/14/2024.

Riccardo Perfetti Insider Trading History at Applied Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2024Sell110,804$5.39$597,233.561,031,537View SEC Filing Icon  
11/30/2023Sell1,583$1.97$3,118.51692,341View SEC Filing Icon  
9/27/2023Sell10,932$2.70$29,516.40693,924View SEC Filing Icon  
1/11/2023Sell6,053$0.91$5,508.23154,856View SEC Filing Icon  
3/23/2022Buy30,000$1.97$59,100.00View SEC Filing Icon  
3/21/2022Buy12,548$1.85$23,213.80View SEC Filing Icon  
8/9/2021Sell15,000$17.39$260,850.0015,000View SEC Filing Icon  
7/28/2021Sell15,000$17.50$262,500.0015,000View SEC Filing Icon  
7/15/2021Sell460$19.54$8,988.40View SEC Filing Icon  
7/13/2021Sell460$21.25$9,775.00View SEC Filing Icon  
6/7/2021Sell460$20.97$9,646.20460View SEC Filing Icon  
6/4/2021Sell460$19.65$9,039.00460View SEC Filing Icon  
5/25/2021Sell460$17.97$8,266.201,640View SEC Filing Icon  
5/11/2021Sell200$17.27$3,454.00200View SEC Filing Icon  
4/30/2021Sell2,560$18.39$47,078.401,640View SEC Filing Icon  
4/28/2021Sell1,640$18.44$30,241.601,640View SEC Filing Icon  
4/14/2021Sell200$17.11$3,422.00200View SEC Filing Icon  
3/30/2021Sell460$18.43$8,477.80465View SEC Filing Icon  
3/26/2021Sell465$19.68$9,151.20465View SEC Filing Icon  
3/15/2021Sell465$19.61$9,118.65465View SEC Filing Icon  
3/12/2021Sell465$19.38$9,011.70465View SEC Filing Icon  
2/25/2021Sell1,295$23.20$30,044.00465View SEC Filing Icon  
2/23/2021Sell465$21.84$10,155.60465View SEC Filing Icon  
2/3/2021Sell1,295$26.79$34,693.053,785View SEC Filing Icon  
2/1/2021Sell1,460$25.30$36,938.003,785View SEC Filing Icon  
1/21/2021Sell465$20.30$9,439.50465View SEC Filing Icon  
1/19/2021Sell465$21.83$10,150.95465View SEC Filing Icon  
1/8/2021Sell16,515$23.23$383,643.457,765View SEC Filing Icon  
1/6/2021Sell7,765$23.47$182,244.557,765View SEC Filing Icon  
12/29/2020Sell465$21.95$10,206.75465View SEC Filing Icon  
12/9/2020Sell465$20.46$9,513.90465View SEC Filing Icon  
12/7/2020Sell465$20.49$9,527.85465View SEC Filing Icon  
11/23/2020Sell465$20.59$9,574.351,660View SEC Filing Icon  
11/20/2020Sell1,660$19.07$31,656.201,660View SEC Filing Icon  
11/10/2020Sell200$17.59$3,518.00200View SEC Filing Icon  
10/29/2020Sell465$17.27$8,030.55465View SEC Filing Icon  
10/27/2020Sell465$21.20$9,858.00465View SEC Filing Icon  
See Full Table

Riccardo Perfetti Buying and Selling Activity at Applied Therapeutics

This chart shows Riccardo Perfetti's buying and selling at Applied Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Therapeutics Company Overview

Applied Therapeutics logo
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $6.80
Low: $6.75
High: $7.17

50 Day Range

MA: $4.84
Low: $2.49
High: $7.40

2 Week Range

Now: $6.80
Low: $0.76
High: $9.39

Volume

1,506,542 shs

Average Volume

2,222,632 shs

Market Capitalization

$720.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82